Ramalho, Diogo and Araújo, André and Rocha, Gustavo and Duarte-Ribeiro, Filipa (2021) Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related? European Journal of Case Reports in Internal Medicine, 8 (12). pp. 1-5. ISSN 2284-2594
|
Text
3099-Article Text-26427-1-10-20211229.pdf - Published Version Download (295kB) | Preview |
Abstract
Pituitary adenomas are the most common cause of hypopituitarism associated with pituitary enlargement, but other aetiologies have been emerging, namely immune checkpoint inhibitor-induced hypophysitis (ipilimumab, nivolumab and pembrolizumab). Secukinumab is a recently approved human monoclonal antibody used for the treatment of psoriasis, with no know reported cases of hypophysitis. We describe a challenging case of panhypopituitarism in a patient with a pituitary incidentaloma and a temporal relationship between secukinumab initiation and the manifestation of clinical features suggestive of hypopituitarism. In such intricate work-up, the differential diagnoses should be carefully considered, taking into account the therapeutic and prognostic implications.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Pituitary neoplasms, hypophysitis, hypopituitarism, secukinumab |
| Subjects: | 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 15 Mar 2022 16:51 |
| Last Modified: | 15 Mar 2022 16:51 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21755 |
Actions (login required)
 |
View Item |
